Compare Cadila Healthcare with Suven Life Sciences - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs SUVEN LIFE SCIENCES - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE SUVEN LIFE SCIENCES CADILA HEALTHCARE/
SUVEN LIFE SCIENCES
 
P/E (TTM) x 29.7 -86.3 - View Chart
P/BV x 5.2 1.4 384.0% View Chart
Dividend Yield % 0.7 1.7 39.1%  

Financials

 CADILA HEALTHCARE   SUVEN LIFE SCIENCES
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-20
SUVEN LIFE SCIENCES
Mar-19
CADILA HEALTHCARE/
SUVEN LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs352338 104.3%   
Low Rs207169 121.9%   
Sales per share (Unadj.) Rs139.252.1 267.1%  
Earnings per share (Unadj.) Rs11.86.8 172.2%  
Cash flow per share (Unadj.) Rs18.68.6 216.7%  
Dividends per share (Unadj.) Rs3.501.50 233.3%  
Dividend yield (eoy) %1.30.6 211.7%  
Book value per share (Unadj.) Rs101.465.3 155.2%  
Shares outstanding (eoy) m1,023.74127.28 804.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.04.9 41.3%   
Avg P/E ratio x23.737.1 64.0%  
P/CF ratio (eoy) x15.029.6 50.9%  
Price / Book Value ratio x2.83.9 71.0%  
Dividend payout %29.822.0 135.5%   
Avg Mkt Cap Rs m286,03332,272 886.3%   
No. of employees `00013.41.1 1,238.9%   
Total wages/salary Rs m24,145661 3,651.7%   
Avg. sales/employee Rs Th10,632.76,132.2 173.4%   
Avg. wages/employee Rs Th1,801.2611.1 294.8%   
Avg. net profit/employee Rs Th898.5803.5 111.8%   
INCOME DATA
Net Sales Rs m142,5316,635 2,148.2%  
Other income Rs m1,139242 470.1%   
Total revenues Rs m143,6706,877 2,089.0%   
Gross profit Rs m24,1981,604 1,508.4%  
Depreciation Rs m6,965221 3,145.9%   
Interest Rs m3,41838 9,066.3%   
Profit before tax Rs m14,9541,587 942.0%   
Minority Interest Rs m2880-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,198718 445.4%   
Profit after tax Rs m12,044869 1,385.3%  
Gross profit margin %17.024.2 70.2%  
Effective tax rate %21.445.2 47.3%   
Net profit margin %8.513.1 64.5%  
BALANCE SHEET DATA
Current assets Rs m87,1546,232 1,398.4%   
Current liabilities Rs m82,6941,490 5,549.6%   
Net working cap to sales %3.171.5 4.4%  
Current ratio x1.14.2 25.2%  
Inventory Days Days7186 82.6%  
Debtors Days Days9483 113.6%  
Net fixed assets Rs m133,2364,043 3,295.2%   
Share capital Rs m1,024127 804.4%   
"Free" reserves Rs m102,7338,183 1,255.5%   
Net worth Rs m103,7578,310 1,248.6%   
Long term debt Rs m32,14618 180,595.5%   
Total assets Rs m236,86610,389 2,280.0%  
Interest coverage x5.443.1 12.5%   
Debt to equity ratio x0.30 14,463.9%  
Sales to assets ratio x0.60.6 94.2%   
Return on assets %6.58.7 74.8%  
Return on equity %11.610.5 110.9%  
Return on capital %13.719.5 70.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m52,7525,622 938.4%   
Fx outflow Rs m14,5041,799 806.0%   
Net fx Rs m38,2483,822 1,000.6%   
CASH FLOW
From Operations Rs m25,054356 7,047.5%  
From Investments Rs m-10,123-279 3,633.5%  
From Financial Activity Rs m-10,942-225 4,861.0%  
Net Cashflow Rs m3,989-148 -2,691.6%  

Share Holding

Indian Promoters % 74.8 63.4 118.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 0.0 -  
FIIs % 5.9 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 36.5 30.1%  
Shareholders   44,069 37,287 118.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   IPCA LABS  SANOFI INDIA  ALEMBIC PHARMA  PROCTER & GAMBLE HEALTH  NOVARTIS  

Compare CADILA HEALTHCARE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Flat; Wipro & Hindalco Industries Among Top Nifty Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On...(Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Apr 16, 2021 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 5-YR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS